普華和順(01358.HK):CBPO上半年實現銷售2.74億美元
格隆匯 8 月 18日丨普華和順(01358.HK)發佈公告,CBPO(公司的主要經營聯營公司,於納斯達克上市)公佈其2020年第二季度及上半年的未經審核財務業績,2020年第二季度,CBPO實現銷售1.11億美元,毛利7637.43萬美元,CBPO應占淨收入3568.17萬美元,CBPO應占非美國公認會計原則經調整淨收入4343.97萬美元。
2020年上半年,CBPO實現銷售2.74億美元,毛利1.77億美元,CBPO應占淨收入8906.61萬美元,CBPO應占非美國公認會計原則經調整淨收入1.05億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.